By demethylating the CSPG4 promoter, decitabine converts over 50% of treated ovarian cancer cells into CSPG4-positive targets, enabling effective targeting by CSPG4-specific CAR T-cells. The gene discussed is CSPG4; the disease is ovarian carcinoma.